Who are Tamoxifen + Aminoglutethimide's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Orserdu, Nextstellis, Cerianna, Duavee, Osphena, Duavee.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/tamoxifen-aminoglutethimide.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Tamoxifen + Aminoglutethimide — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Tamoxifen + Aminoglutethimide (Tamoxifen + Aminoglutethimide) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: SERM and CYP11A1 inhibitor. Area: Oncology.

phase 3 SERM and CYP11A1 inhibitor estrogen receptor Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Tamoxifen + Aminoglutethimide (Tamoxifen + Aminoglutethimide) — Austrian Breast & Colorectal Cancer Study Group. Tamoxifen acts as a selective estrogen receptor modulator (SERM) to inhibit estrogen's action in breast tissue, while aminoglutethimide inhibits the enzyme CYP11A1, which is involved in the synthesis of steroids, including estrogen.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Tamoxifen + Aminoglutethimide TARGET	Tamoxifen + Aminoglutethimide	Austrian Breast & Colorectal Cancer Study Group	phase 3	SERM and CYP11A1 inhibitor	estrogen receptor
Orserdu	ELACESTRANT	Stemline Therap	marketed	Estrogen Receptor Antagonist [EPC]	Estrogen receptor	2023-01-01
Nextstellis	ESTETROL	Mayne Pharma	marketed	Estrogen	Estrogen receptor	2021-01-01
Cerianna	FLUOROESTRADIOL F-18	GE HealthCare	marketed	Radioactive Diagnostic Agent [EPC]	Estrogen receptor	2020-01-01
Duavee	conjugated-estrogens-bazedoxifene	Pfizer	marketed	Estrogen [EPC]	estrogen receptors α and β	2013-01-01
Osphena	OSPEMIFENE	Duchesnay	marketed	Estrogen Agonist/Antagonist [EPC]	Estrogen receptor beta	2013-01-01
Duavee	BAZEDOXIFENE	Wyeth Pharms Pfizer	marketed	Estrogen [EPC]	estrogen receptors (ER) α and β	2013-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2027-03-10 — Duavee · 7683051 · US

Sponsor landscape (SERM and CYP11A1 inhibitor class)

Austrian Breast & Colorectal Cancer Study Group · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Tamoxifen + Aminoglutethimide — Competitive Intelligence Brief. https://druglandscape.com/ci/tamoxifen-aminoglutethimide. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab